Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Mouse|
|Host / Isotype||Rat / IgG2a|
|Storage buffer||PBS with 4-5mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1 ug /10^6 cells|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-17794 targets CD19 in FACS applications and shows reactivity with Mouse samples.
The MA5-17794 immunogen is mouse CD19.
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It is expressed on approximately 10% of normal human peripheral blood cells and approximately 60% of splenic lymphocytes. It is not expressed on granulocytes, monocytes or T cells as defined by CD3 expression. CD19 defines a pan B antigen which is expressed from the earliest stages of B progenitor development, but is lost on terminal differentiation to plasma cells. It may also be present on some early myeloid progenitors, particularly those of the monoblastic type. The CD19 antigen is expressed on approximately 12% of peripheral blood lymphocytes. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
AW495831; B-lymphocyte antigen CD19; CD19; Differentiation antigen CD19